Cargando…

A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease

Characterisation and diagnosis of idiopathic Parkinson’s disease (iPD) is a current challenge that hampers both clinical assessment and clinical trial development with the potential inclusion of non-PD cases. Here, we used a targeted mass spectrometry approach to quantify 38 metabolites extracted fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Klatt, Stephan, Doecke, James D., Roberts, Anne, Boughton, Berin A., Masters, Colin L., Horne, Malcolm, Roberts, Blaine R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516864/
https://www.ncbi.nlm.nih.gov/pubmed/34650080
http://dx.doi.org/10.1038/s41531-021-00239-x
_version_ 1784583886220558336
author Klatt, Stephan
Doecke, James D.
Roberts, Anne
Boughton, Berin A.
Masters, Colin L.
Horne, Malcolm
Roberts, Blaine R.
author_facet Klatt, Stephan
Doecke, James D.
Roberts, Anne
Boughton, Berin A.
Masters, Colin L.
Horne, Malcolm
Roberts, Blaine R.
author_sort Klatt, Stephan
collection PubMed
description Characterisation and diagnosis of idiopathic Parkinson’s disease (iPD) is a current challenge that hampers both clinical assessment and clinical trial development with the potential inclusion of non-PD cases. Here, we used a targeted mass spectrometry approach to quantify 38 metabolites extracted from the serum of 231 individuals. This cohort is currently one of the largest metabolomic studies including iPD patients, drug-naïve iPD, healthy controls and patients with Alzheimer’s disease as a disease-specific control group. We identified six metabolites (3-hydroxykynurenine, aspartate, beta-alanine, homoserine, ornithine (Orn) and tyrosine) that are significantly altered between iPD patients and control participants. A multivariate model to predict iPD from controls had an area under the curve (AUC) of 0.905, with an accuracy of 86.2%. This panel of metabolites may serve as a potential prognostic or diagnostic assay for clinical trial prescreening, or for aiding in diagnosing pathological disease in the clinic.
format Online
Article
Text
id pubmed-8516864
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-85168642021-10-29 A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease Klatt, Stephan Doecke, James D. Roberts, Anne Boughton, Berin A. Masters, Colin L. Horne, Malcolm Roberts, Blaine R. NPJ Parkinsons Dis Article Characterisation and diagnosis of idiopathic Parkinson’s disease (iPD) is a current challenge that hampers both clinical assessment and clinical trial development with the potential inclusion of non-PD cases. Here, we used a targeted mass spectrometry approach to quantify 38 metabolites extracted from the serum of 231 individuals. This cohort is currently one of the largest metabolomic studies including iPD patients, drug-naïve iPD, healthy controls and patients with Alzheimer’s disease as a disease-specific control group. We identified six metabolites (3-hydroxykynurenine, aspartate, beta-alanine, homoserine, ornithine (Orn) and tyrosine) that are significantly altered between iPD patients and control participants. A multivariate model to predict iPD from controls had an area under the curve (AUC) of 0.905, with an accuracy of 86.2%. This panel of metabolites may serve as a potential prognostic or diagnostic assay for clinical trial prescreening, or for aiding in diagnosing pathological disease in the clinic. Nature Publishing Group UK 2021-10-14 /pmc/articles/PMC8516864/ /pubmed/34650080 http://dx.doi.org/10.1038/s41531-021-00239-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Klatt, Stephan
Doecke, James D.
Roberts, Anne
Boughton, Berin A.
Masters, Colin L.
Horne, Malcolm
Roberts, Blaine R.
A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease
title A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease
title_full A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease
title_fullStr A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease
title_full_unstemmed A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease
title_short A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease
title_sort six-metabolite panel as potential blood-based biomarkers for parkinson’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516864/
https://www.ncbi.nlm.nih.gov/pubmed/34650080
http://dx.doi.org/10.1038/s41531-021-00239-x
work_keys_str_mv AT klattstephan asixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease
AT doeckejamesd asixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease
AT robertsanne asixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease
AT boughtonberina asixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease
AT masterscolinl asixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease
AT hornemalcolm asixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease
AT robertsblainer asixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease
AT klattstephan sixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease
AT doeckejamesd sixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease
AT robertsanne sixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease
AT boughtonberina sixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease
AT masterscolinl sixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease
AT hornemalcolm sixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease
AT robertsblainer sixmetabolitepanelaspotentialbloodbasedbiomarkersforparkinsonsdisease